

Parawee Chevairakul

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2718329/parawee-chevairakul-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16
papers

330
citations

7
h-index

17
g-index

17
ext. papers

393
ext. citations

2.9
avg, IF

2.55
L-index

#	Paper	IF	Citations
16	Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. <i>The Lancet Regional Health - Western Pacific</i> , 2021 , 15, 100240	5	2
15	Regulatory T Cell Suppressive Activity Predicts Disease Relapse During Disease-Modifying Anti-rheumatic Drug Dose Reduction in Rheumatoid Arthritis: A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2020 , 7, 25	4.9	0
14	Inhibitory activity of FOXP3+ regulatory T cells reveals high specificity for displaying immune tolerance in remission state rheumatoid arthritis. <i>Scientific Reports</i> , 2020 , 10, 19789	4.9	5
13	Efficient short-term expansion of human peripheral blood regulatory T cells for co-culture suppression assay. <i>Journal of Immunoassay and Immunochemistry</i> , 2019 , 40, 573-589	1.8	4
12	Clinical spectrums and outcomes of necrotizing autoimmune myopathy versus other idiopathic inflammatory myopathies: a multicenter case-control study. <i>Clinical Rheumatology</i> , 2019 , 38, 3459-3469	3.9	6
11	SAT0007 THE SUPPRESSIVE ACTIVITY OF PERIPHERAL BLOOD TREG REPRESENTS IMMUNOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS PATIENTS 2019 ,		1
10	Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor α Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 9-15	1.1	2
9	Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 170-178	2.3	13
8	2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1166-1184	2.3	7
7	Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1142-1165	2.3	5
6	Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis. <i>Sleep Medicine</i> , 2016 , 23, 26-45	4.6	96
5	Angiotensin-converting enzyme gene polymorphism in Thai patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2016 , 19, 693-9	2.3	3
4	APLAR rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 685-713	2.3	93
3	Risk of tuberculosis with anti-tumor necrosis factor- α therapy: substantially higher number of patients at risk in Asia. <i>International Journal of Rheumatic Diseases</i> , 2014 , 17, 291-8	2.3	53
2	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012 , 22, 15-20	3.3	23
1	The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. <i>International Journal of Rheumatic Diseases</i> , 2009 , 12, 118-24	2.3	14